Primary Objective: Evaluate the efficacy and safety of eliglustat in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3. Secondary Objective: Evaluate the quality of life in Chinese pediatric patients (≥12 to \<18 years old) with Gaucher disease type 1 and type 3 treated with eliglustat.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in hemoglobin level
Timeframe: Baseline, Weeks 13, 26, 39 and 52
Changes in platelet count
Timeframe: Baseline, Weeks 13, 26, 39 and 52
Changes in spleen volume
Timeframe: Baseline, Weeks 26 and 52
Changes in liver volume
Timeframe: Baseline, Weeks 26 and 52
Changes in Lyso-GL1 level
Timeframe: Baseline, Weeks 13, 26, 39 and 52
Skeletal improvement
Timeframe: Baseline, Weeks 26 and 52
Assessment of pharmacokinetic (PK) parameter of eliglustat: Cmax
Timeframe: Baseline, Weeks 2, 13, 26 and 52
Assessment of pharmacokinetic (PK) parameter of eliglustat: Ctrough
Timeframe: Baseline, Weeks 2, 13, 26 and 52
Adverse events
Timeframe: Up to Week 52